Skip to content
Screener

Corvus Pharmaceuticals CRVS Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.25B-11.7%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$21.83M-41.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$64.17M+15.9%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$43.6M+32.1%

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.17B+247%
Enterprise value$1.13B+250%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-057100
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Net (loss) income per share, basic$(0.15)$0.21
Net loss per share, diluted$(0.15)$(0.13)
Shares used to compute net (loss) income per share, basic89,996,72872,126,496
Shares used to compute net loss per share, diluted89,996,72875,152,514
Other comprehensive (loss) income:
Unrealized loss on marketable securities(334)(23)
Cumulative foreign currency translation adjustment10457
Comprehensive (loss) income$(13,922)$15,227

Item 1. Financial Statements (unaudited)

FAQ

What is Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Corvus Pharmaceuticals (CRVS) reported comprehensive income (loss), net of tax, attributable to parent of -$13.92M in Q1 2026.
How has Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 191.4% year-over-year, from $15.23M to -$13.92M.
What is the long-term trend for Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a -22.5% compound annual growth rate (CAGR), from -$41.38M to -$14.89M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This is a comprehensive measure of all changes in equity during a period, excluding transactions with owners, encompassing both net income and other comprehensive income items. It provides a holistic view of the company's total financial performance by including unrealized gains or losses that bypass the traditional income statement. Investors use this to evaluate the total economic impact of all financial activities on the company's net worth.

Ask your AI about Corvus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude